2nd Abu Dhabi Brain Conference 2022 Program Book

21% n=142 n=74 n=183 11% n=235 35% P <0.0001 P =0.0009 27% n=397 59% n=295 43% PAIN h FREEDOM h PAIN h Co-primary endpoints 1 Secondary endpoint 1 Placebo (n=682) Nurtec ODT 75 mg (n=669) -3.5 n=347 -4.3 * n=348 Placebo (n=347) Rimegepant 75mg (n=348) * P =0.0099 60% Nearly of patients achieved pain relief at 2 housr 1 21% n=142 n=74 n=183 11% n=235 35% P <.001 P =.001 27% n=397 59% n=295 43% PAIN h FREEDOM h PAIN h Co-primary endpoints 1 Secondary endpoint 1 Nurtec ODT 75 mg (n=669) P <.001 % OF PATIENTS Nurtec ODT demonstrated superiority over placebo at 2 hours post dose in treating pain and most bothersome symptoms 1 Treating migraine attacks Patients treated with rimegepant demonstrated a signi cant reduction inmeanMMDs with EOD dosing 2 Reduction in MMDs during weeks 9-12 2 EOD=every other day; MMDs=monthly migraine days. REDUCTION IN MMDs 2 Primary endpoint at weeks 9-12 Placebo (n=682) REFERENCES: 1. Croop R, Goadsby PJ, Stock DA, et al. E cacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394 (10200):737-745. 2. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60. Adapted from Croop R, Goadsby PJ, Stock DA, et al. 2019 Adapted from Croop R, Lipton RB, Kudrow D, et al. 2021 Point estimate